Why wooo ashtool?
RECENT HIGHLIGHTS
$3.7 million cash burn
- Record quarter for ADAPT sales which continue to accelerate.
- Net cash outflows reduced by 23% over the previous quarter (excluding the R&D rebate).
- Quarterly underlying sales1 are up 16% on the prior quarter.
- Two separate patent applications for TAVR technologies were filed in the
US.
- A new funding facility was arranged for up to $10.0M in secured debt from Partners for Growth (after quarter close).
- Entered into an exclusive supply agreement for TMVR with 4C Medical.
- CardioCel® 3D moved from a pre-market programme to an expanded
access programme.
- The new Royal Adelaide Hospital (nRAH) officially opened on
5 September 2017 – poised to positively impact infusion business sales.
Ann: Appendix 4C - quarterly, page-3
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
-0.500(3.19%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.75 | $15.75 | $15.00 | $294.3K | 19.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1135 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.35 | 88 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |